Question ID:PT72 S2 Q17 Passage:The government health service has said that it definitely will not pay for patients to take the influenza medicine Antinfia until the drug's manufacturer, PharmCo, provides detailed information about Antinfia's cost-effectiveness. PharmCo has responded that obtaining such information would require massive clinical trials. These trials cannot be performed until the drug is in widespread circulation, something that will happen only if the government health service pays for Antinfia. Stem:If the statements of both the government health service and PharmCo are true, which one of the following is most likely to also be true? Correct Answer Choice:BChoice A:The government health service never pays for any medicine unless that medicine has been shown to be cost-effective. Choice B:Antinfia will never be in widespread circulation. Choice C:If the government health service does not pay for Antinfia, then many patients will pay for Antinfia themselves. Choice D:The government health service should pay for patients to take Antinfia. Choice E:Antinfia is not cost-effective.